Horizon Pharma said in a release that a proposed generic version of its Pennsaid topical pain reliever has been sidelined in the U.S. by a court ruling upholding Horizon Pharma's patent infringement claim.
Based in Dublin, Ireland, Horizon Pharma had filed a claim in 2015 to stop Actavis Laboratories UT from making and selling a version of the medication containing diclofenac sodium topical solution 2 percent.
The U.S. District Court for the District of New Jersey ruled May 15 that Actavis' version of the pain reliever, often used to treat arthritis pain, would have violated Horizon’s patent, set to run out in 2030.
Pennsaid 2 percent contains a non-steroidal anti-inflammatory drug as well as other ingredients to aid absorption and can be dosed via a pump.
